|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
|
31750938 |
2020 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2- Advanced/Metastatic Breast Cancer.
|
31662535 |
2020 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this retrospective, single-center cohort study we evaluated real-world use of first-line palbociclib with aromatase inhibitor (AI) treatment in HR-positive, HER2-negative metastatic breast cancer patients who received treatment between February 2015 and July 2017.
|
31451366 |
2020 |
|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with HER2-mutant metastatic breast cancer.
|
31806627 |
2020 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
The HER2-intermediate patients more frequently tended to have progesterone receptor (PR)-negativity and higher nuclear grade in the EBC cohort, and showed a higher proportion of patients aged ≥ 55 years compared with the HER2-negative group in the MBC cohort.
|
31811505 |
2020 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pubmed, Embase, the Cochrane Library, and ClinicalTrials.gov were searched for randomized controlled trials that evaluated any taxanes+HER2-targeted agents in the treatment of HER2<sup>+</sup> MBC.
|
31529262 |
2020 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among 16 702 patients recorded in the ESME MBC database, 10 595 had an initially localised breast cancer with hormone receptor (HR) and HER2 status available, with a metastatic recurrence.Median follow up was 56 months.
|
31675683 |
2020 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Baseline plasma cell-free DNA (cfDNA) from 164 postmenopausal women with ER-positive, HER2-negative MBC refractory to a non-steroidal aromatase inhibitor and treated with standard EVE/EXE (Everolimus Biomarker Study, Eudract 2013-004120-11) was characterised for 10 relevant breast cancer genes by next generation sequencing with molecular barcoding. ctDNA molecule numbers, number of mutations and specific variants were related with PFS and overall survival (OS).
|
31841262 |
2020 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
This article summarizes FDA decision-making and data supporting the approval of palbociclib for the treatment of male patients with HR-positive, HER2-negative advanced or MBC.
|
31649043 |
2020 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
We review the latest recommendations and supporting evidence for endocrine therapy in women with hormone receptor-positive/HER2-negative metastatic breast cancer and discuss strategies for the optimal sequential therapy in scenarios of response to endocrine therapy.
|
31849236 |
2020 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients.
|
31612291 |
2020 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
We sequenced cfDNA of a hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) cohort with a high coverage to examine the prevalence and relevance of any detected variant. cfDNA of 44 MBC patients was isolated, followed by library construction using a customized targeted DNA panel with integrated unique molecular indices analyzing AKT1, AR, BRCA1, BRCA2, EGFR, ERCC4, ERBB2, ERBB3, ESR1, FGFR1, KRAS, MUC16, PIK3CA, PIK3R1, PTEN, PTGFR, and TGFB1.
|
31254045 |
2020 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Main inclusion criteria for screening were as follows: women with HER2-negative MBC treated with ≥ 2 prior lines of chemotherapy and measurable disease.
|
31727113 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2- Metastatic Breast Cancer: Biological Mechanisms and New Treatments.
|
31450618 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor approved for use in postmenopausal women with hormone receptor-positive, human epidermal growth factor 2-negative (HR+/HER2-) advanced/metastatic breast cancer (ABC/MBC).
|
30391832 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Takotsubo Cardiomyopathy During Anti-HER2 Therapy for Metastatic Breast Cancer.
|
30389744 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
This real-world study estimated the proportion of women with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2‒) mBC who may be at risk of developing QTc prolongation.
|
30792074 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
This 3 + 3 dose-escalation study of S-1 given for the first 2 of 3 weeks, in combination with T-DM1 (3.6 mg/kg given every 3 weeks) to patients with trastuzumab-pretreated HER2-positive advanced or metastatic breast cancer was designed to evaluate the dose-limiting toxicity (DLT) occurrence in the first cycle.
|
30893699 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a second-line endocrine therapy for hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR<sup>+</sup>/HER2<sup>-</sup>) metastatic breast cancer, palbociclib has demonstrated significant efficacy in prolonging progression-free survival when added to a regimen containing fulvestrant.
|
31104762 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.
|
31142370 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
The principal selection criteria were HER2 negativity without previous chemotherapy for MBC, the previous use of taxanes for early-stage breast cancer, and a DFI of < 36 months (subsequently amended to 48 months).
|
30679100 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
In fact, pertuzumab plus trastuzumab and docetaxel is the recommended first line regimen in HER2 positive locally recurrent or metastatic breast cancer and bevacizumab plus paclitaxel or docetaxel is a reasonable option for m-TNBC.
|
29424297 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
|
31446213 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Five patients who had human epidermal growth factor receptor 2 (HER2) negative MBC were recruited in this study.
|
31810960 |
2019 |
|
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We retrospectively screened patients with metastatic breast cancer in whom molecular profiling had been performed using next-generation sequencing from 2012 to 2015; we identified 18 patients with HER2 mutation.
|
31351155 |
2019 |